

NDA 19950/S-066 and S-067

SUPPLEMENT APPROVAL

Pfizer Inc
Attention: Michele Burtness
Senior Manager
Pfizer Essential Health Global Regulatory Affairs Brands
235 East 42nd Street
New York, NY 10017

Dear Ms. Burtness:

Please refer to your supplemental new drug applications (sNDAs) dated March 2, 2017, (S-066) and April 6, 2017 (S-067), and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Diflucan (fluconazole in dextrose injection and fluconazole in sodium chloride injection).

These Prior Approval supplemental new drug applications provide for a separate package insert for the injection formulation and incorporate changes in the Diflucan Tablets (NDA 19949) and Diflucan Powder for Oral Suspension (NDA 20090) package inserts approved on February 7, 2019, March 9, and January 22, 2018, and October 27, 2017. Important updates include:

- 1) Removal of the pregnancy category from the **PRECAUTIONS** section, **Pregnancy, Teratogenic Effects** subsection, and addition of risk mitigation for treatment of serious fungal infections information.
- 2) Revised the **WARNINGS** section to rename the subsection title from **Use in Pregnancy** to **Potential for Fetal Harm**. This change was also made in the **PRECAUTIONS** section, **Pregnancy, Teratogenic Effects** subsection.
- 3) Updates to the **ADVERSE REACTIONS** section, **Post-Marketing Experience** subsection, *Skin and Appendages*.
- 4) Addition of Q-T prolongation information to the **PRECAUTIONS** section, **General** subsection, and addition of a potential drug interaction with Amiodarone to the **PRECAUTIONS** section, **Drug Interactions** subsection.
- 5) Updates to the **PRECAUTIONS** section, **General, Nursing Mothers** subsection.
- 6) Updates to the **CLINICAL PHARMACOLOGY** section, **Pharmacokinetics and Metabolism** and **Microbiology** subsections, **PRECAUTIONS** section, **General, Drug Interactions**, and **Nursing Mothers** subsections, **DOSAGE AND ADMINISTRATION** section, *Dosage In Patients with Impaired Renal Function*, and the **REFERENCES** section.

Additional changes, specific only to the injection formulation include:

- 1) The established name has been revised from Fluconazole Injection – for intravenous infusion only to Fluconazole in Dextrose Injection and Fluconazole in Sodium Chloride Injection, for intravenous use.
- 2) Removal of the tablet and oral suspension information from the **DESCRIPTION**, **DOSAGE AND ADMINISTRATION**, and **HOW SUPPLIED** sections.
- 3) Removal of the vaginal candidiasis (*vaginal yeast infections due to Candida*) indication from the **INDICATIONS AND USAGE**, and **CLINICAL STUDIES** sections.
- 4) Removal of references to the single dose treatment from the **PRECAUTIONS** section, **General** subsection, and the **ADVERSE REACTIONS**, and **DOSAGE AND ADMINISTRATION** sections.
- 5) Removal of the **PATIENT INFORMATION**.

APPROVAL & LABELING

We have completed our review of these applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.²

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for these NDAs, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in these supplemental applications, as well as annual reportable changes. To facilitate review of your submission(s), provide a

¹ <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Alison Rodgers, Regulatory Project Manager, at 301-796-0797.

Sincerely,

{See appended electronic signature page}

Dmitri Iarikov, MD, PhD
Deputy Director
Division of Anti-Infectives
Office of Infectious Diseases
Center for Drug Evaluation and Research

ENCLOSURE:

- Content of Labeling
 - Prescribing Information

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

DMITRI IARIKOV
11/07/2019 11:33:55 AM